2020
Can Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents?
Merriam A, Paidas M. Can Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents? 2020, 223-230. DOI: 10.1201/9780429450303-24.ChaptersRecurrent pregnancy lossPregnancy outcomesAntiplatelet agentsPregnancy lossAntithrombotic agentsMultiple adverse pregnancy outcomesSmall case-control studyAntiplatelet agent aspirinAdverse pregnancy outcomesSuccessful pregnancy outcomeCase-control studyMultiple prospective studiesHistory of thrombophiliaClass of drugsEffects of anticoagulantsAspirin treatmentProspective studyAnticoagulant agentsLive birthsThrombophiliaBlood clotsWomenAspirinOutcomesAgents
2016
Thrombophilia and Pregnancy
Hendrix P, Tinelli A, Malvasi A, Paidas M. Thrombophilia and Pregnancy. 2016, 287-313. DOI: 10.1007/978-3-319-31377-1_13.Peer-Reviewed Original ResearchAdverse pregnancy outcomesPregnancy outcomesHereditary thrombophiliaBest practice clinical guidelinesContinuum of pregnancyVenous thromboembolic eventsRecurrent fetal lossIntrauterine growth restrictionProthrombin gene mutationNatural anticoagulant protein SFactor V LeidenEfficacy of preventionFetal morbidityThromboembolic eventsAntiphospholipid syndromeMaternal riskPuerperal periodClinical guidelinesFetal lossGrowth restrictionTreatment paradigmV LeidenRisk associationThrombophiliaPregnancy
2012
Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort
LYKKE JA, BARE LA, OLSEN J, LAGIER R, ARELLANO AR, TONG C, PAIDAS MJ, LANGHOFF‐ROOS J. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. Journal Of Thrombosis And Haemostasis 2012, 10: 1320-1325. PMID: 22578003, DOI: 10.1111/j.1538-7836.2012.04773.x.Peer-Reviewed Original ResearchConceptsMethylenetetrahydrofolate reductase (MTHFR) C677TFetal growth restrictionProthrombin mutation G20210APlacental abruptionSevere preeclampsiaGrowth restrictionAllelic modelAdverse pregnancy outcomesBody mass indexCase-cohort studyReductase C677TPreterm deliveryComposite outcomePregnancy outcomesMass indexPregnant womenMedical recordsC677TFV LeidenStudy designSocioeconomic statusPreeclampsiaAbruptionRandom controlsOutcomes
2008
73: Increased risk of maternal mortality from cardiovascular and non-cardiovascular causes following adverse pregnancy outcome in first delivery
Lykke J, Langhoff-Roos J, Triche E, Lockwood C, Paidas M. 73: Increased risk of maternal mortality from cardiovascular and non-cardiovascular causes following adverse pregnancy outcome in first delivery. American Journal Of Obstetrics And Gynecology 2008, 199: s33. DOI: 10.1016/j.ajog.2008.09.098.Peer-Reviewed Original ResearchAdverse pregnancy outcomesNon-cardiovascular causesPregnancy outcomesMaternal mortalityFirst deliveryMortalityAntithrombotic Therapy and Pregnancy: Consensus Report and Recommendations for Prevention and Treatment of Venous Thromboembolism and Adverse Pregnancy Outcomes
Duhl A, Paidas M, Ural S, Branch W, Casele H, Cox-Gill J, Hamersley S, Hyers T, Katz V, Kuhlmann R, Nutescu E, Thorp J, Zehnder J. Antithrombotic Therapy and Pregnancy: Consensus Report and Recommendations for Prevention and Treatment of Venous Thromboembolism and Adverse Pregnancy Outcomes. Obstetric Anesthesia Digest 2008, 28: 137-138. DOI: 10.1097/01.aoa.0000326376.74250.dd.Peer-Reviewed Original Research
2007
Thromboembolic Disorders of Pregnancy
Paidas M, Pettker C, Lockwood C. Thromboembolic Disorders of Pregnancy. 2007, 825-848. DOI: 10.1002/9780470753293.ch47.ChaptersRecurrent adverse pregnancy outcomesAdverse pregnancy outcomesVenous thromboembolismPregnancy outcomesPregnancy treatmentPregnancy managementRisk factorsRadiation exposureAnemia risk factorsThromboembolic disordersAnticoagulationThromboembolismPregnancyThrombophiliaSurgeryDiagnosisPharmacologyWomenOutcomesTreatmentExposure
2005
Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications
PAIDAS MJ, KU D, LEE M, MANISH S, THURSTON A, LOCKWOOD CJ, ARKEL YS. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. Journal Of Thrombosis And Haemostasis 2005, 3: 497-501. PMID: 15748239, DOI: 10.1111/j.1538-7836.2005.01158.x.Peer-Reviewed Original ResearchConceptsAdverse pregnancy outcomesNormal pregnancy outcomeProtein S levelsPZ levelsPregnancy outcomesProtein SSubsequent pregnancy complicationsProtein ZAdditional risk factorsFree PS antigenPregnancy complicationsPregnant controlsThird trimesterPlasma levelsRisk factorsPatientsThrombophiliaPS antigenS levelsWomenSignificant decreasePS levelsOutcomesLow levelsTrimester
2004
Term Decidual Cell Thrombomodulin and Endothelial Protein C Receptor Expression Is Upregulated by Thrombin Irrespective of Ovarian Hormonal Priming.
Paidas M, Ku D, Arkel Y, Tang C, Fortunato C, Lockwood C. Term Decidual Cell Thrombomodulin and Endothelial Protein C Receptor Expression Is Upregulated by Thrombin Irrespective of Ovarian Hormonal Priming. Blood 2004, 104: 1947. DOI: 10.1182/blood.v104.11.1947.1947.Peer-Reviewed Original ResearchAdverse pregnancy outcomesDecidual cellsExpression of TMReal-time PCRAddition of hirudinEndothelial protein C receptor expressionTime PCRIntrauterine growth restrictionPro-inflammatory processesMaternal-fetal interfaceTM protein expressionProtein C systemHormonal primingUteroplacental thrombosisWestern blot analysisAbruptio placentaeGeneration of APCCesarean sectionPregnancy outcomesNormal pregnancyProthrombotic milieuUncomplicated pregnanciesFetal interfaceGestational ageMedroxy progesteroneProtein S Free Antigen Levels and the Occurrence of IgG and IgM Antibodies to Protein S in Normal Pregnancy.
Arkel Y, Ku D, Paidas M, Fortunato C, Ku E, Lockwood C. Protein S Free Antigen Levels and the Occurrence of IgG and IgM Antibodies to Protein S in Normal Pregnancy. Blood 2004, 104: 3993. DOI: 10.1182/blood.v104.11.3993.3993.Peer-Reviewed Original ResearchAdverse pregnancy outcomesNormal pregnancyIgM antibodiesProtein SPS IgGAntigen levelsReference rangeFree PS antigen levelsEvaluation of thrombophiliaPS antigen levelsNon-pregnant controlsNumber of patientsNon-pregnant donorsNon-pregnant valuesOccurrence of IgGAnticardiolipin syndromeProthrombotic processesPregnancy patientsPregnancy outcomesAutoimmune diseasesTrimester samplesHemostatic systemImmune responseHigh riskPregnancyThe Occurrence of Antibodies to Components of the Natural Coagulation Inhibitor System, Protein Z and Protheombin in Normal Pregnancy.
Ku D, Arkel Y, Paidas M, Triche E, Huang S, Musto J, Lockwood C. The Occurrence of Antibodies to Components of the Natural Coagulation Inhibitor System, Protein Z and Protheombin in Normal Pregnancy. Blood 2004, 104: 3995. DOI: 10.1182/blood.v104.11.3995.3995.Peer-Reviewed Original ResearchNon-pregnant controlsAnti-PC IgMAdverse pregnancy outcomesNormal pregnancyIgM antibodiesPS IgGOccurrence of antibodiesAnticardiolipin syndromeProthrombotic processesPregnancy outcomesAntibody levelsMost pregnanciesAutoimmune diseasesAntibody responseIgG antibodiesHemostatic balanceImmune responseTrimesterCoagulation factorsChronic responsesPregnancyIgMIgGGestationAntibodiesElevated sEPCR and PAI-1 Levels, but Not sThrombomodulin Levels in Normal Pregnancy.
Arkel Y, Paidas M, Ku D, Triche E, Lam X, Ku E, Lockwood C. Elevated sEPCR and PAI-1 Levels, but Not sThrombomodulin Levels in Normal Pregnancy. Blood 2004, 104: 3996. DOI: 10.1182/blood.v104.11.3996.3996.Peer-Reviewed Original ResearchEndothelial protein C receptorAdverse pregnancy outcomesPro-inflammatory cytokinesNormal pregnancyProtein C systemDecidual cellsEndothelial cellsProtein SEndometrial decidual cellsNon-pregnant controlsProtein C receptorCell surface proteinsPlasminogen activator inhibitorCell-surface thrombomodulinPregnancy outcomesProthrombotic statePlasma thrombomodulinNP patientsEC damageSurface proteinsControl of thrombosisSTM levelsTrimester samplesPregnancyFibrinolytic systemPregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system
Paidas M, Ku D, Lee M, Lockwood C, Arkel Y. Pregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system. Journal Of Thrombosis And Haemostasis 2004, 2: 840-841. PMID: 15099295, DOI: 10.1111/j.1538-7836.2004.00680.x.Peer-Reviewed Original Research
2003
Human decidual cells express components of the activated protein c system: a model for prothrombotic related adverse pregnancy outcomes
Paidas M, Ku D, Arkel Y, Schatz F, Tang C, Rahman M, Thurston A, Lockwood C. Human decidual cells express components of the activated protein c system: a model for prothrombotic related adverse pregnancy outcomes. American Journal Of Obstetrics And Gynecology 2003, 189: s190. DOI: 10.1016/j.ajog.2003.10.481.Peer-Reviewed Original ResearchRelated adverse pregnancy outcomesAdverse pregnancy outcomesHuman decidual cellsProtein C systemPregnancy outcomesDecidual cells
2001
17 First trimester thrombus precursor protein (TPP) predicts adverse pregnancy outcome in thrombophilic patients
Paidas M, Urban G, Ku W, Arkel Y, Dilley A, Andrei R, Kuczynski E, Jeanine M, Mignosa M, Khan S, Schoenfeld J, Lockwood C. 17 First trimester thrombus precursor protein (TPP) predicts adverse pregnancy outcome in thrombophilic patients. American Journal Of Obstetrics And Gynecology 2001, 185: s76. DOI: 10.1016/s0002-9378(01)80027-2.Peer-Reviewed Original ResearchAdverse pregnancy outcomesThrombus precursor proteinPregnancy outcomesThrombophilic patientsPrecursor proteinPatients